Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clinics (Sao Paulo). 2011;66(12):2141-9.

Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?

Author information

  • 1Neonatal Intensive Care Unit, Puericulture Institute And Neonatal Section, AOU University of Cagliari, Italy.

Abstract

Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.

PMID:
22189742
[PubMed - indexed for MEDLINE]
PMCID:
PMC3226612
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Scientific Electronic Library Online Icon for PubMed Central
    Loading ...
    Write to the Help Desk